|
NZ603111A
(en)
|
2001-08-03 |
2014-05-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
JP4653109B2
(ja)
|
2003-11-05 |
2011-03-16 |
ロシュ グリクアート アクチェンゲゼルシャフト |
高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
|
|
NZ556286A
(en)
|
2005-02-07 |
2010-11-26 |
Glycart Biotechnology Ag |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
|
|
CN101500597A
(zh)
|
2005-06-17 |
2009-08-05 |
伊姆克罗尼系统公司 |
治疗转移性骨癌的受体拮抗剂
|
|
JP5373396B2
(ja)
*
|
2005-08-26 |
2013-12-18 |
ロシュ グリクアート アクチェンゲゼルシャフト |
改変された細胞シグナル活性有する改変抗原結合分子
|
|
KR101353706B1
(ko)
|
2006-02-03 |
2014-02-18 |
유니버시티 오브 워싱톤 |
전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
CA2689941C
(en)
|
2007-06-25 |
2019-10-29 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
|
ES2449070T3
(es)
|
2007-09-05 |
2014-03-18 |
F. Hoffmann-La Roche Ag |
Terapia de combinación con anticuerpos anti-CD20 de tipo I y tipo II
|
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
JP2011507897A
(ja)
*
|
2007-12-21 |
2011-03-10 |
ジェネンテック， インコーポレイテッド |
リツキシマブ抵抗性関節リウマチ患者の治療
|
|
RU2540013C2
(ru)
*
|
2008-03-13 |
2015-01-27 |
Биотест Аг |
Средство для лечения заболевания
|
|
JP5604311B2
(ja)
*
|
2008-03-13 |
2014-10-08 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
|
CN102027017A
(zh)
*
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
|
TWI500624B
(zh)
*
|
2008-03-25 |
2015-09-21 |
Hoffmann La Roche |
具有增進之抗體依賴型細胞毒性之第ii型抗－ｃｄ２０抗體之組合療法
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CA2722466A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2297208A4
(en)
*
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
SG191639A1
(en)
*
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
KR20110031369A
(ko)
*
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
CA2738598C
(en)
*
|
2008-09-29 |
2017-11-21 |
Biotest Ag |
Composition for treating disease
|
|
US20100247484A1
(en)
*
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
BRPI1012589A2
(pt)
|
2009-04-07 |
2016-03-22 |
Roche Glycart Ag |
anticorpos bi-específicos anti-erbb-3/anti-c-met
|
|
EP2417160A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-1/anti-c-met antibodies
|
|
ES2537100T3
(es)
|
2009-04-07 |
2015-06-02 |
Roche Glycart Ag |
Anticuerpos biespecíficos trivalentes
|
|
US8815242B2
(en)
*
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
RU2012109451A
(ru)
*
|
2009-08-14 |
2013-09-27 |
Роше Гликарт Аг |
Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
|
|
TWI409079B
(zh)
*
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
|
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗ｃｄｃｐ１抗體
|
|
RU2012112550A
(ru)
*
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
TW201119676A
(en)
*
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
MX2012007340A
(es)
|
2009-12-22 |
2012-08-01 |
Roche Glycart Ag |
Anticuerpos anti/her3 y usos de los mismos.
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
EP2601218A4
(en)
|
2010-08-03 |
2015-02-18 |
Abbvie Inc |
VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
|
AR082693A1
(es)
*
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
|
EP2609111B1
(en)
|
2010-08-24 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising a disulfide stabilized-fv fragment
|
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
KR20130088170A
(ko)
*
|
2010-12-16 |
2013-08-07 |
로슈 글리카트 아게 |
비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
|
HK1200850A1
(en)
|
2011-09-23 |
2015-08-14 |
罗氏格黎卡特股份公司 |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
TW201945034A
(zh)
|
2011-09-30 |
2019-12-01 |
日商中外製藥股份有限公司 |
包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
|
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
|
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
|
JP6309002B2
(ja)
|
2012-06-27 |
2018-04-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
|
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
|
RU2636043C2
(ru)
|
2012-11-01 |
2017-11-17 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
WO2014067642A1
(en)
|
2012-11-05 |
2014-05-08 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
|
MX365567B
(es)
|
2013-03-13 |
2019-06-07 |
Genentech Inc |
Formulaciones de anticuerpo.
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
|
JP2017501157A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
|
|
TWI689520B
(zh)
|
2014-05-30 |
2020-04-01 |
漢霖生技股份有限公司 |
抗表皮生長因子受體（ｅｇｆｒ）抗體
|
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
|
US20170313779A1
(en)
*
|
2014-11-05 |
2017-11-02 |
The University Of Chicago |
Methods and compositions pertaining to human cerebral cavernous malformations
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CN107592812A
(zh)
*
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
MX2017016651A
(es)
*
|
2015-06-24 |
2018-05-14 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
|
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
|
EP3960765A1
(en)
|
2015-06-26 |
2022-03-02 |
Sanofi Biotechnology SAS |
Monoclonal anti-il-1racp antibodies
|
|
AU2016285596A1
(en)
|
2015-06-29 |
2018-01-18 |
Genentech, Inc. |
Type II anti-CD20 antibody for use in organ transplantation
|
|
HRP20200390T1
(hr)
|
2015-08-03 |
2020-06-12 |
Engmab Sàrl |
Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
JP2019515874A
(ja)
*
|
2016-03-01 |
2019-06-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
改変された細胞死誘導を有するオビヌツズマブ変異体
|
|
JP2019516352A
(ja)
*
|
2016-04-01 |
2019-06-20 |
アムジエン・インコーポレーテツド |
Ｆｌｔ３に対するキメラ受容体及びその使用方法
|
|
US11649284B2
(en)
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
|
US10148939B2
(en)
|
2016-07-19 |
2018-12-04 |
Gopro, Inc. |
Mapping of spherical image data into rectangular faces for transport and decoding across networks
|
|
IL266424B2
(en)
|
2016-11-02 |
2023-09-01 |
Engmab Sarl |
A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
|
|
IL267406B2
(en)
|
2016-12-20 |
2025-05-01 |
Hoffmann La Roche |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
WO2019020606A1
(en)
|
2017-07-26 |
2019-01-31 |
F. Hoffmann-La Roche Ag |
POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
|
|
WO2019036433A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CN119074915A
(zh)
|
2018-03-13 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
4-1bb激动剂与抗cd20抗体的治疗剂组合
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN112996801A
(zh)
*
|
2018-11-26 |
2021-06-18 |
北卡罗来纳州大学 |
用于捕获宿主细胞蛋白的肽配体
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
MX2021015540A
(es)
*
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
|
US20220275065A1
(en)
*
|
2019-07-31 |
2022-09-01 |
The Wistar Institute Of Anatomy And Biology |
Multivalent dna antibody constructs and use thereof
|
|
JP2022547577A
(ja)
|
2019-09-12 |
2022-11-14 |
ジェネンテック， インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
|
KR20220086618A
(ko)
|
2019-10-18 |
2022-06-23 |
제넨테크, 인크. |
미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
CN111411079B
(zh)
*
|
2020-03-27 |
2025-12-12 |
北京时合生物科技有限公司 |
细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
|
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
|
EP4149547A4
(en)
|
2020-05-13 |
2024-08-14 |
Adagene AG |
Compositions and methods for treating cancer
|
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
|
TW202434286A
(zh)
|
2022-11-08 |
2024-09-01 |
美商建南德克公司 |
治療兒童期發病的特發性腎病症候群之組成物及方法
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|